Ardsley Advisory Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Ardsley Advisory Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$639K	Hold	300,000	–	–	0.07%	133
2026 Q1	$507K	Buy	300,000 +250,000	+500%	+$1.1M	0.06%	140
2025 Q4	$259K	Buy	+50,000	New	+$257K	0.03%	138
2025 Q2	–	Sell	-400,000	Closed	-$2.3M	–	150
2025 Q1	$2.3M	Sell	400,000 -200,000	-33%	-$1.18M	0.44%	76
2024 Q4	$2.99M	Buy	+600,000	New	+$3.08M	0.47%	71

Other funds holding ALDX

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Ardsley Advisory Partners's ALDX Position: Q2 2026 in Review

Ardsley Advisory Partners increased its Aldeyra Therapeutics (ALDX) stake by 2.6% in Q2 2026, buying an estimated $43K and bringing the position to 975,000 shares worth $2.08M. The position accounts for 0.22% of the portfolio, ranked #103.

Ardsley Advisory Partners first reported a position in ALDX in Q2 2017 and has held it in 22 quarters since. The position peaked at $9.92M in Q3 2025. 10 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Ardsley Advisory Partners held 975,000 shares of Aldeyra Therapeutics worth $2.08M as of Q2 2026.
Ardsley Advisory Partners bought 25,000 Aldeyra Therapeutics shares in Q2 2026, an estimated $43K.
Aldeyra Therapeutics made up 0.22% of Ardsley Advisory Partners's portfolio in Q2 2026, its #103 holding.
Ardsley Advisory Partners first reported a position in Aldeyra Therapeutics in Q2 2017 and has held it in 22 quarters since.
Ardsley Advisory Partners's Aldeyra Therapeutics position peaked at $9.92M in Q3 2025.
10 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.